Funding
This research was supported by the National Natural Science Foundation
of China (8190335).
Data availability statement
The data underlying this article are available in the FDA adverse events
reporting system (FAERS). The datasets were derived from sources in the
public domain:
https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
Ethics statement
The Medical Research Ethics Review Committee of the First Affiliated
Hospital of Chongqing Medical University decided to waive the original
ethic application procedure, based on the reason that the open public
database used in this project.
References
1. Roizman, B., Whither herpesviruses? Adv Exp Med Biol, 1990.278 : p. 285-91.
2. Crimi, S., et al., Herpes Virus, Oral Clinical Signs and QoL:
Systematic Review of Recent Data. Viruses, 2019. 11 (5).
3. Abb, J., [Prevention and therapy of herpesvirus
infections]. Zentralbl Bakteriol Mikrobiol Hyg B, 1985.180 (2-3): p. 107-20.
4. Grinde, B., Herpesviruses: latency and reactivation - viral
strategies and host response. J Oral Microbiol, 2013. 5 .
5. Verweij, M.C., et al., Viral inhibition of the transporter
associated with antigen processing (TAP): a striking example of
functional convergent evolution. PLoS Pathog, 2015. 11 (4): p.
e1004743.
6. Griffin, B.D., M.C. Verweij, and E.J. Wiertz, Herpesviruses and
immunity: the art of evasion. Vet Microbiol, 2010. 143 (1): p.
89-100.
7. Elion, G.B., et al., Selectivity of action of an antiherpetic
agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A,
1977. 74 (12): p. 5716-20.
8. van Diemen, F.R. and R.J. Lebbink, CRISPR/Cas9, a powerful tool
to target human herpesviruses. Cell Microbiol, 2017. 19 (2).
9. Castro, A.A., A.I. Cordoves, and P.A. Farias, Determination of
the antiretroviral drug acyclovir in diluted alkaline electrolyte by
adsorptive stripping voltammetry at the mercury film electrode. Anal
Chem Insights, 2013. 8 : p. 21-8.
10. Wei, Y.P., et al., Critical Review of Synthesis, Toxicology
and Detection of Acyclovir. Molecules, 2021. 26 (21).
11. De Clercq, E. and G. Li, Approved Antiviral Drugs over the
Past 50 Years. Clin Microbiol Rev, 2016. 29 (3): p. 695-747.
12. King, D.H., History, pharmacokinetics, and pharmacology of
acyclovir. J Am Acad Dermatol, 1988. 18 (1 Pt 2): p. 176-9.
13. van de Sand, L., et al., Antiviral Active Compounds Derived
from Natural Sources against Herpes Simplex Viruses. Viruses, 2021.13 (7).
14. Xu, F., et al., Seroprevalence of herpes simplex virus type 1
in children in the United States. J Pediatr, 2007. 151 (4): p.
374-7.
15. Gonçalves, B.C., et al., Antiviral therapies: advances and
perspectives. Fundam Clin Pharmacol, 2021. 35 (2): p. 305-320.
16. Mlynarczyk-Bonikowska, B., et al., Antiviral medication in
sexually transmitted diseases. Part I: HSV, HPV. Mini Rev Med Chem,
2013. 13 (13): p. 1837-45.
17. Majewska, A. and B. Mlynarczyk-Bonikowska, 40 Years after the
Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs? Int J
Mol Sci, 2022. 23 (7).
18. Coen, D.M. and P.A. Schaffer, Antiherpesvirus drugs: a
promising spectrum of new drugs and drug targets. Nat Rev Drug Discov,
2003. 2 (4): p. 278-88.
19. Chakrabarty, A., et al., Emerging therapies for herpes viral
infections (types 1 - 8). Expert Opin Emerg Drugs, 2004. 9 (2):
p. 237-56.
20. Agut, H., et al., Testing the susceptibility of human
herpesviruses to antivirals. Future Microbiol, 2009. 4 (9): p.
1111-23.
21. Lehto, J.T., et al., Human herpesvirus-6 and -7 after lung and
heart-lung transplantation. J Heart Lung Transplant, 2007.26 (1): p. 41-7.
22. Lee, D.H. and R.A. Zuckerman, Herpes simplex virus infections
in solid organ transplantation: Guidelines from the American Society of
Transplantation Infectious Diseases Community of Practice. Clin
Transplant, 2019. 33 (9): p. e13526.
23. Perera, M.R., M.R. Wills, and J.H. Sinclair, HCMV Antivirals
and Strategies to Target the Latent Reservoir. Viruses, 2021.13 (5).
24. Rodriguez, E.M., J.A. Staffa, and D.J. Graham, The role of
databases in drug postmarketing surveillance. Pharmacoepidemiol Drug
Saf, 2001. 10 (5): p. 407-10.
25. Humar, A., et al., The efficacy and safety of 200 days
valganciclovir cytomegalovirus prophylaxis in high-risk kidney
transplant recipients. Am J Transplant, 2010. 10 (5): p.
1228-37.
26. Märtson, A.G., et al., Therapeutic Drug Monitoring of
Ganciclovir: Where Are We? Ther Drug Monit, 2022. 44 (1): p.
138-147.
27. Takahata, M., et al., Occurrence of adverse events caused by
valganciclovir as pre-emptive therapy for cytomegalovirus infection
after allogeneic stem cell transplantation is reduced by low-dose
administration. Transpl Infect Dis, 2015. 17 (6): p. 810-5.
28. Paya, C., et al., Efficacy and safety of valganciclovir vs.
oral ganciclovir for prevention of cytomegalovirus disease in solid
organ transplant recipients. Am J Transplant, 2004. 4(4): p. 611-20.